fulacimstat

chymase inhibitor

Also Known As:

1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-((1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid; 5-Pyrimidinecarboxylic acid, 1-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)-3-((1R)-2,3-dihydro-4-(trifluoromethyl)-1H-inden-1-yl)-1,2,3,4-tetrahydro-2,4-dioxo-; BAY 1142524

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Becka, Michael: 4 articles (12/2021 - 01/2019)
2.	Kanefendt, Friederike: 4 articles (12/2021 - 01/2019)
3.	Otto, Christiane: 4 articles (12/2021 - 01/2019)
4.	Senni, Michele: 2 articles (01/2020 - 10/2019)
5.	Avogaro, Angelo: 1 article (12/2021)
6.	Rossing, Peter: 1 article (12/2021)
7.	Strand, Jorma: 1 article (12/2021)
8.	Admon, Dan: 1 article (01/2020)
9.	Duengen, Hans-Dirk: 1 article (01/2020)
10.	GROUP investigators of the CHIARA MIA 2 trial: 1 article (01/2020)

Related Diseases

1.	Myocardial Infarction 01/01/2019 - "The absence of blood pressure effects after administration of BAY 1142524 supports the combination of this novel anti-remodeling drug with existing standard of care in patients with left-ventricular dysfunction after acute myocardial infarction." 01/01/2020 - "Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial." 10/01/2019 - "Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial." 10/01/2019 - "The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). " 01/01/2019 - "The orally available chymase inhibitor BAY 1142524 is currently being developed as a first-in-class treatment for left-ventricular dysfunction after myocardial infarction. "
2.	Left Ventricular Dysfunction 01/01/2020 - "Fulacimstat was safe and well tolerated in patients with left-ventricular dysfunction (LVD) after first STEMI but had no effect on cardiac remodeling." 01/01/2019 - "The absence of blood pressure effects after administration of BAY 1142524 supports the combination of this novel anti-remodeling drug with existing standard of care in patients with left-ventricular dysfunction after acute myocardial infarction." 10/01/2019 - "Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial." 10/01/2019 - "The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). " 01/01/2019 - "The orally available chymase inhibitor BAY 1142524 is currently being developed as a first-in-class treatment for left-ventricular dysfunction after myocardial infarction. "
3.	Diabetic Nephropathies (Diabetic Nephropathy) 12/02/2021 - "Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial."
4.	Diabetes Mellitus 12/02/2021 - "This study investigated the effects of the chymase inhibitor fulacimstat on albuminuria in patients with Type II diabetes mellitus and a clinical diagnosis of DKD. "
5.	Albuminuria 12/02/2021 - "Fulacimstat was safe and well tolerated but did not reduce albuminuria in patients with DKD. " 12/02/2021 - "This study investigated the effects of the chymase inhibitor fulacimstat on albuminuria in patients with Type II diabetes mellitus and a clinical diagnosis of DKD. "

Related Drugs and Biologics

1.	Chymases (Chymase)
2.	4- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)